相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment
Eugenio Mercuri et al.
EUROPEAN JOURNAL OF NEUROLOGY (2023)
Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study
Astrid Pechmann et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2023)
Nusinersen for adults with spinal muscular atrophy
Doruk Arslan et al.
NEUROLOGICAL SCIENCES (2023)
Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route
Chunyan Jia et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2023)
Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
Claudia A. A. Chiriboga et al.
NEUROLOGY AND THERAPY (2023)
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
Richard S. Finkel et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2023)
Intrahepatic Cholestasis Is a Clinically Significant Feature Associated with Natural History of X-Linked Myotubular Myopathy (XLMTM): A Case Series and Biopsy Report
Cristina Molera et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2022)
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2022)
Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features
Peter H. Hagedorn et al.
NUCLEIC ACID THERAPEUTICS (2022)
Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study
Claudia Weiss et al.
LANCET CHILD & ADOLESCENT HEALTH (2022)
Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys
Francis Fonyuy Tukov et al.
HUMAN GENE THERAPY (2022)
Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA
Kotaro Yazaki et al.
NEUROLOGY (2022)
Evaluating the state of the science for adeno-associated virus integration: An integrated perspective
Denise E. Sabatino et al.
MOLECULAR THERAPY (2022)
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Kevin A. Strauss et al.
NATURE MEDICINE (2022)
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A. Strauss et al.
NATURE MEDICINE (2022)
Research Paper Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program
Deepa H. Chand et al.
PEDIATRIC NEUROLOGY (2022)
Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice
Dhwanil A. Dalwadi et al.
MOLECULAR THERAPY (2021)
Fourth Boy Dies in Clinical Trial of Astellas' AT132
Alex Philippidis
HUMAN GENE THERAPY (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2021)
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
Gretchen Thomsen et al.
NATURE MEDICINE (2021)
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa Chand et al.
JOURNAL OF HEPATOLOGY (2021)
Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
Andrada Mirea et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Tamara Dangouloff et al.
NEUROMUSCULAR DISORDERS (2021)
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Jerry R. Mendell et al.
JAMA NEUROLOGY (2021)
Delivery of Therapeutic Agents to the Central Nervous System and the Promise of Extracellular Vesicles
Charlotte A. Rene et al.
PHARMACEUTICS (2021)
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1
Kelly F. Oechsel et al.
MUSCLE & NERVE (2021)
Growth patterns in children with spinal muscular atrophy
Ramona De Amicis et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease
Crystal Jing Jing Yeo et al.
PEDIATRIC NEUROLOGY (2020)
Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV
Leon Morales et al.
MOLECULAR THERAPY (2020)
Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes
Megan A. Waldrop et al.
PEDIATRICS (2020)
Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy
Renske Wadman et al.
BRAIN COMMUNICATIONS (2020)
Abnormal fatty acid metabolism is a core component of spinal muscular atrophy
Marc-Olivier Deguise et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Impaired kidney structure and function in spinal muscular atrophy
Flavia C. Nery et al.
NEUROLOGY-GENETICS (2019)
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Christian Hinderer et al.
HUMAN GENE THERAPY (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
Lodewijk J. A. Toonen et al.
NUCLEIC ACID THERAPEUTICS (2018)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Natural history of infantile-onset spinal muscular atrophy
Stephen J. Kolb et al.
ANNALS OF NEUROLOGY (2017)
Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients
Irene Gil-Farina et al.
MOLECULAR THERAPY (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates
Kathrin Meyer et al.
MOLECULAR THERAPY (2015)
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Jean-Charles Nault et al.
NATURE GENETICS (2015)
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell et al.
MOLECULAR THERAPY (2014)
Observational study of spinal muscular atrophy type I and implications for clinical trials
Richard S. Finkel et al.
NEUROLOGY (2014)
Recombinant Adeno-Associated Virus Integration Sites in Murine Liver After Ornithine Transcarbamylase Gene Correction
Li Zhong et al.
HUMAN GENE THERAPY (2013)
Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and III
Allan M. Glanzman et al.
JOURNAL OF CHILD NEUROLOGY (2011)
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Marco A. Passini et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients
Jessica M. O'Hagen et al.
NEUROMUSCULAR DISORDERS (2007)
Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver
Peter Bell et al.
MOLECULAR THERAPY (2006)
No evidence for tumorigenesis of AAV vectors in a large-scale study in mice
P Bell et al.
MOLECULAR THERAPY (2005)
Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
M Feldkötter et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
A Donsante et al.
GENE THERAPY (2001)